ArticleInternational ophthalmology2021
Transepithelial photorefractive keratectomy to treat mild myopia.
Article in International ophthalmology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 13 citations in OpenAlex.
- One-Year Visual and Refractive Outcomes of SmartPulseJournal of clinical medicine · 2024Article
- Short-Term Visual and Refractive Outcomes of Single-Step Transepithelial Photorefractive Keratectomy with Amaris 750S and SmartSurfLife (Basel, Switzerland) · 2024Article
- Article
- Refractive results of photorefractive keratectomy comparing trans-PRK and PTK-PRK for correction of myopia and myopic astigmatism.International ophthalmology · 2024Article
- StreamLight Single-Step Transepithelial Photorefractive Keratectomy (PRK) for Myopia and Myopic Astigmatism.Journal of ophthalmology · 2024Article
- The effect of incomplete blinking rate on corneal epithelial remodeling after trans-PRK surgery: a six-month study.Frontiers in medicine · 2023Article
- Transepithelial Photorefractive Keratectomy Compared to Conventional Photorefractive Keratectomy: A Meta-Analysis.Journal of ophthalmology · 2022Review
- Effect of Prophylactic Mitomycin C on Corneal Endothelium Following Transepithelial Photorefractive Keratectomy in Myopic Patients.Clinical ophthalmology (Auckland, N.Z.) · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo assess the safety and effectiveness of transepithelial photorefractive keratectomy (T-PRK) in patients with mild myopia using the Schwind Amaris 750 s Excimer laser system which take corneal epithelium variability in consideration during ablation.
methodsA prospective case series study of patients with mild myopia with or without astigmatism (spherical equivalent ≤ -3 diopters), who underwent T-PRK as a single-step treatment, was carried out at King Abdulaziz University Hospital, Riyadh between May 2017 and January 2018. The main outcomes included postoperative uncorrected distance visual acuity (UDVA), residual refraction (manifest refraction) and complications.
resultsA total of 42 patients (84 eyes) underwent bilateral T-PRK with a preoperative spherical equivalent ranging from - 0.75 to - 3.00 D. Median spherical equivalent before Trans-PRK was - 1.75 (- 1.25to - 1.75). The spherical equivalent six months after Trans-PRK was 0.0 (- 0.25 to 0.5). All patients had a postoperative UDVA of 20/20 or better in the last follow-up. Transient postoperative corneal haze was observed in five eyes (6%).
conclusionT-PRK appears to be safe and effective in patients who have mild myopia, with or without astigmatism. The normal variation in corneal epithelial thickness seems not to affect the outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.